Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Sep
09
Today In Oncology
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
New Data on 14- vs 28-Day Venetoclax/Azacitidine in AML
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
SUO/AUA Updates Guidelines for Non-Muscle Invasive Bladder Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo